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Abstract The German Psoriasis Registry PsoBest was
conducted in 2008 in order to investigate the long-term
outcomes and safety of systemic treatments for moderate-
to-severe psoriasis. Safety analysis of antipsoriatic drugs
with special focus on serious adverse events (SAE) for
infections, malignancies and major cardiac events (MACE)
was done. Nationwide non-interventional patient treatment
registry conducted in 251 active dermatology centers. Until
June 2012, n = 2444 patients [40 % female; mean age 47.3
(SD 14.1) years; mean duration of disease 18.2 (SD 14.7)
years] were recruited, including n = 1791 patients (3842
patient years) with conventional systemic drugs and
n = 908 (3442 patient years) with biological drugs. Mean
PASI (Psoriasis Area and Severity Index) at inclusion was
14.7, mean DLQI (Dermatology Life Quality Index) 11.1,
mean BMI (Body Mass Index) 28.2. The overall rate of
SAE per 100 patient years were 1.3 (SD 0.9) per 100
patient years in conventional systemic and 1.5 (SD 1.2) in
biologics (p[ 0.5, no significant difference). The rates per
100 patient years for single severe adverse events were as
follows (systemic/biologics): serious infections, 0.33/0.65
[CI (confidence interval) 0.13–0.54/0.35–0.98]; MACE,
0.56/0.77 (CI 0.29–0.97/0.41–1.31); malignancies (except
non-melanoma skin cancer), 0.46/0.49 (CI 0.22–0.84/
0.21–0.97). There were no significant differences between
single drugs in any of the safety parameters. The conven-
tional systemic and biologic drugs for psoriasis show sat-
isfying safety under routine psoriasis care in Germany with
respect to infections, MACE and malignancies.
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Introduction
According to evidence-based guidelines, systemic drugs
are treatments of choice for patients with moderate-to-
severe psoriasis [13, 16]. In most countries, first-line sys-
temic treatment includes methotrexate, ciclosporin A and
retinoids, whereas the second-line treatment is based on the
biologics infliximab, etanercept, ustekinumab and adali-
mumab for plaque type psoriasis and psoriatic arthritis, and
golimumab for psoriatic arthritis. Only in Germany fumaric
acid esters (FAE) are licensed for first-line treatment.
Showing a chronic, persisting course of disease, psoriasis
requires a long-term strategy for treatment over many
decades [2, 3].
The German Psoriasis Registry PsoBest records safety,
long-term efficacy, patient benefit and treatment regimens
of psoriasis. Patients with moderate or severe psoriasis are
included in PsoBest, when treatment with a conventional
systemic agent or biologic is started for the first time.
Observation time is extended to 10 years.
One of the major objectives of the patient registry
PsoBest is the evaluation of safety and outcomes in
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systemic treatment of plaque type psoriasis and psoriatic
arthritis [4]. The present analysis presents long-term safety
outcomes from PsoBest with a special focus on severe
infections, malignancies and major adverse cardiovascular
events (MACE). The questions addressed were as follows:
1. How is the overall safety of conventional systemic
drugs and biologics in the treatment of moderate-to-
severe psoriasis and psoriatic arthritis?
2. In particular, are there any differences between the
various treatments with respect to safety signals on
severe infections, malignancies and MACE?
Materials and methods
Patient registry
All patients considered in the analysis were observed in
The German Psoriasis Registry PsoBest [4]. This patient
registry includes adult patients with moderate-to-severe
psoriasis at the time point of a new drug to be started. The
observation time for the patient is 10 years regardless of
the treatment applied. Follow-up visits in the dermatology
office are conducted in intervals of 3 months in the first
half-year and every 6 months afterwards. In addition,
3 months after the physician visits, the patients are directly
approached by mail for further information on the treat-
ment status and patient reported outcomes. Patients without
at least one follow-up visit are excluded from analysis,
because of missing validation of therapy information.
Patients were assigned to biologic cohort when they have
been registered on adalimumab, etanercept, infliximab or
ustekinumab. Starting a conventional systemic treatment
with ciclosporin, fumaric acid ester or methotrexate,
patients were referred to systemic treatment.
The outcomes measured in PsoBest follow the European
consensus in the PsoNet network [14, 17, 18] and are thus
harmonized with patient registries on psoriasis from other
countries. Moreover, the assessment of safety has been
adapted to the German registry on biologics and rheuma-
toid arthritis [19] and the international recommendations
released in Europe [8, 11] and the United States [1, 10].
The registry conductance conforms to the German national
guidance on patient registries [12]. In this guidance, an
explicit set of requirements both on the study planning,
conductance and data analysis is included. The quality
assurance of the registry PsoBest follows the recommen-
dations by controlling for structural, process and outcomes
quality. The overall supervision of the standard operating
procedures for PsoBest based on the guidances was pro-
vided by a DIN ISO 9001:2008 certification (certificate ID
170549705). Scientific quality is warranted by a scientific
advisory board of German psoriasis experts. Regular
annual investigator meetings and quarterly newsletters are
provided in order to maintain high quality of investigator
performance.
Adverse events
In this analysis, only prospectively observed events were
considered. Any event was classified serious (serious
adverse event) in context of in-patient stay, life-threatening
circumstances, neoplasms and death. All events observed
were divided into 9 classes regarding infections, cardio-
vascular events and malignancies. Events, which are not
matching any class, e.g., gastrointestinal disorders are not
shown.
Infections were divided into ‘serious’—in the context of
in-patient stay or life-threatening status, ‘severe’—with
antibiotic prescription—and ‘non-severe’ including all
other infections. Major adverse cardiovascular events are
defined as irreversible events based on vascular obstruction
comprising myocardial infarction, cardiac failure, cardio-
vascular death, acute coronary syndrome, hemiparesis
ischemic stroke and cerebrovascular accident. To prevent
loosing important information on cardiovascular events the
category other cardiovascular events (right ventricular
failure, coronary artery occlusion, cardiac arrest and
myocarditis) was defined. Besides these groups no other
events occurred regarding infections, cardiovascular events
and malignancies. The event-class ‘malignancies’ com-
prises all neoplasms with additional regard to melanoma
and non-melanoma skin cancer.
MedDRA (Medical Dictionary for Regulatory Activi-
ties) preferred terms for investigations as well as for sur-
gical or medical procedures were only considered if they
were single reported events, e.g., ‘tumor excision’ was only
counted as event in malignancies if there was no tumor
reported.
Data analysis
The data analyzed in this study were gained in the time
period from January 01, 2008 to December 31, 2012. The
safety data were separately documented in MedDRA pre-
ferred terms for adverse events and severe adverse events.
The occurring events were attributed to the last treat-
ment, applied with a 90-day window following the
Manchester template. Only the events of malignancies and
death were assigned to all previous systemic treatments,
regardless of its exposure time. Events occurring within a
combined treatment were assigned to all treatments as
exposed.
The absolute number of events was recorded. All safety
data reported were referred to exposure time (100 patient
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years). Confidence intervals were computed using inverse
Chi-square distribution and significance level 0.05.
Descriptive data comparisons were conducted with safety
data from the international Psolar registry [15; Langley R
et al. Malignancy Events in the Psoriasis Longitudinal
Assessment and Registry (PSOLAR) Study: Current Status
of Observations [unpublished poster presentation] EADV
meeting: Prague; 2012; Leonardi C et al. Serious Infection
Events in the Psoriasis Longitudinal Assessment and
Registry (PSOLAR) Study: Current Status of Observations
[unpublished poster presentation] EADV meeting: Prague;
2012; Naldi L et al. Major Adverse Cardiovascular Events
(MACE) in The Psoriasis Longitudinal Assessment and
Registry (PSOLAR) Study: Current Status of Observations
[unpublished talk] EADV meeting: Prague 2012].
The statistical analysis was conducted with IBM SPSS
Statistics for Microsoft Windows version 18. Analysis was
performed for the groups systemic versus biologic and each
single treatment regarding prior exposure to biologics and
presence of concomitant conventional systemic therapies.
Results
Patient cohort
In total, 2444 patients (40 % women; 634 patients on
biologic, 1584 on conventional systemic treatment; 266
patients without qualifying treatment) were included in the
analysis. Mean age was 47.4 (SD 14.1) years, the mean
duration of disease 18.2 (SD 14.7) years (Table 1). There is
a total exposure time to biologics of 1463 years and 1733
to conventional systemic treatments (Table 2). In total,
there was a significant rate of comorbidity and co-medi-
cation in these patients compared to patients without pso-
riasis (Fig. 1), indicating a higher risk for adverse events in
Table 1 Clinical patient characteristics of The German Psoriasis Registry PsoBest at baseline and number of adverse events and serious adverse
events in the observation time
Total (2444 patients registered) Biologic treatment (634 patients) Systemic treatment (1584 patients)
Number % Number % Number %
Female 975 39.9 230 36.3 651 41.1
Male 1.469 60.1 404 63.7 933 58.9
Psoriasis–arthritis 506 20.7 230 36.3 223 14.1
Total (2444 patients registered) Biologic treatment (634 patients) Systemic treatment (1584 patients)
Mean Min Max SD Valid
measures
Mean Min Max SD Valid
measures
Mean Min Max SD Valid
measures
Age (years) 47.4 18.0 88.0 14.1 2438 48.0 18.0 87.0 13.3 633 46.8 18.0 88.0 14.4 1580
BMI 28.2 14.7 63.3 5.8 2430 28.7 15.0 54.0 5.9 629 28.0 14.7 63.3 5.8 1575
Waist–hip ratio* 0.9 0.6 1.4 0.1 2299 0.9 0.6 1.4 0.1 593 0.9 0.6 1.3 0.1 1498
PASI 14.7 0.0 64.9 9.7 2388 15.1 0.0 64.9 10.3 628 14.4 0.0 64.8 9.5 1544
DLQI 11.2 0.0 30.0 7.1 2395 11.6 0.0 30.0 7.5 621 10.9 0.0 30.0 6.8 1556




18.2 0.0 74.0 14.1 2312 21.9 0.0 62.0 14.1 601 16.9 0.0 74.0 14.0 1500
Observation time
in registry (m)**
16.5 0.0 58.0 15.7 2444 22.0 0.0 58.0 16.2 634 14.5 0.0 55.9 14.7 1584
Number of adverse
events
1.1 0.0 14.0 1.8 2444 1.1 0.0 13.0 1.7 634 1.1 0.0 14.0 1.9 1584
Number of serious
adverse events
0.1 0.0 8.0 0.5 2444 0.2 0.0 4.0 0.5 634 0.1 0.0 8.0 0.5 1584
Differences between treatment groups are marked
* p B 0.01, ** p B 0.001
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patients with psoriasis. Moreover, patients receiving bio-
logics showed significantly higher rates of relevant
comorbidities such as cardiovascular disease, obesity and
diabetes (Fig. 1).
Drug safety
Overall rate of serious adverse events
The overall rate of SAE was 1.3 (SD 0.9) per 100 patient
years in systemic and 1.5 (SD 1.2) in biologics (p[ 0.5, no
significant difference).
Rate of infections
The rate for serious infections was 0.33 (SD 0.20) per 100
patient years in systemic treatments and 0.65 (SD 0.33) in
biologic treatments (p[ 0.05, no significant difference;
Fig. 2). Rates of 0.56 (SD 0.27) and 0.59 (SD 0.31) were
observed for severe infections and rates for non-severe
infections resulted in 4.88 (SD 0.89) in systemic and 7.50
(SD 1.25) in biologics. There were no significant differ-
ences between the status of previous exposure to biologics
or concomitant conventional systemic therapy in biologic
treatments. Patients with previous exposure to biologics
receiving systemic therapies had a higher risk for non-
severe infections (12.5 versus 4.5 regarding previous bio-
logics, 12.2 versus 5.4 regarding concomitant systemic,
p\ 0.05).
Major cardiac adverse event
The MACE rate did not significantly differ between con-
ventional and biologic treatments (0.56 (SD 0.27) versus
0.77 (SD 0.36) per 100 patient years) (Fig. 3). Also, there
were no significant differences between different single
Table 2 Number of exposed
patients and treatment periods
including mean and total
treatment time
Exposition Patients Periods Exposure time per period (m) Total exposure time (years)
Mean Min Max SD
Adalimumab 462 480 15.6 0.0 55.3 14.2 623.0
Etanercept 298 320 13.5 0.0 52.5 13.0 360.5
Infliximab 108 109 14.1 0.0 48.5 12.1 127.9
Ustekinumab 257 264 16.0 0.0 44.4 13.3 351.8
Anti-TNF 756 909 14.7 0.0 55.3 13.6 1111.4
Biologics 908 1173 15.0 0.0 55.3 13.5 1463.3
Cyclosporine 229 246 7.8 0.0 50.6 9.4 160.0
FAE 981 1030 9.4 0.0 55.8 11.7 807.8
Methotrexate 798 861 10.7 0.0 54.5 12.1 765.2
Systemics 1791 2137 9.7 0.0 55.8 11.6 1733.0
Fig. 1 Rates for comorbidity in patients with psoriasis of the PsoBest registry compared to the age- and gender-adjusted rate of the German
normal population (left graph) and comparison between patients started with biologics versus systemic (right graph; n = 2444)
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drugs. Similarly, the rate of other severe cardiovascular
events did not significantly differ between groups.
Rate of malignancies
The overall rate of malignancies (except NMSC) per 100
patient years was 0.46 (SD 0.24) in patients receiving
systemic and 0.49 (SD 0.28) in patients receiving biologics
(p[ 0.5, no significant differences, n = 2444); Fig. 4.
There were no relevant differences between any drugs with
respect to ‘‘all malignancies except non-melanoma skin
cancer’’, ‘‘non-melanoma skin cancer’’ and ‘‘melanoma
skin cancer’’.
Discussion
Patient treatment registries are large databases reflecting
real-world and long-term courses of disease. For psoriasis a
series of national registries with comparable data sets has
Fig. 2 Rates per 100 patient years of infections (non-severe, severe and serious) in psoriasis patients with systemic and biological drugs
(n = 2444), bars show confidence interval
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been established in Europe, in order to gain robust data on
safety, tolerability and outcomes of systemic drugs
including biologics. The present data analysis from The
German Psoriasis Registry PsoBest intended to gain first
safety information on antipsoriatic drugs in German routine
care. Baseline data indicate that patients in the registry
could have a higher risk for cardiovascular complications
since comorbidity rates are elevated when compared to
age-adjusted population-based rates. This potential bias
needs to be considered when analyzing any registry data
for safety. If compared to the overall cohort of psoriasis
patients, selection events in the registries may occur due to
variations in the access to treatments within a country or—
even more—between countries [9]; e.g., it is remarkable
that in most countries the proportion of women receiving
biologics (but not systemic) is much lower than of men.
The results of recent publications of psoriasis registries
from different countries, however, are in line with our
findings, suggesting no increased risk of serious or fatal AE
in biologics compared to conventional systemics [5, 7].
Further limitations of registries derive from the fact that
there is no random assignment of treatments. Thus, dif-
ferent treatment groups may show structural inequalities,
which can confound results. For this, direct comparisons
between drugs are limited, if not adjusted for the inho-
mogeneities. In the current analysis, no specific adjust-
ments for baseline differences were performed, since the
unadjusted outcomes indicate very low rates of safety
signals across all treatment arms. Another limiting factor is
the limited number of patients included in the analysis.
Thus, small differences and rare events may have been
missed. Since the inclusions into the registry are ongoing,
data analyses will be conducted repeatedly. With respect to
generalizability of the data, it needs to be taken into
account that the current safety outcomes on patients with
moderate-to-severe psoriasis may not be transferable to
patients exposed to these drugs with other diseases; e.g., it
has been shown that there is a different safety profile for
different rheumatologic diseases [6]. Overall, these limi-
tations which are mostly inherent to patient safety registries
need to be considered. In contrast, the data’s strength is the
non-selective character providing external validity and the
systematic approach of nationwide solicited real-world
safety data acquisition.
In total, with respect to safety signals, there have not
been observed any indications for elevated risks of using
Fig. 3 Rates per 100 patient years of MACE (major cardiac events) and other severe cardiovascular events in psoriasis patients with systemic
and biological drugs (n = 2444), bars show confidence interval
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systemic or biologic drugs for psoriasis in Germany. When
compared to international data, like the Psolar registry—
which mostly recruited patients in North America—the
rates for the safety indicators are in the same range. For
example, overall rates for neoplasms were 0.5/0.5 for
systemic/biologics in PsoBest and 0.6/0.6 in Psolar, all data
related to 100 patient years. Similarly, rates for all MACE
were 1.0/0.8 in PsoBest and 1.1/1.3 in Psolar. Greater
differences, but still on a low level, were found for the rates
of overall severe infections (0.6/0.6 in PsoBest and 1.6/1.2
in Psolar). These differences may derive from variations in
attributing infection events to non-severe, severe or serious
types.
In conclusion, this analysis from The German Psoriasis
Registry PsoBest confirms pharmacovigilance data from
other registries, indicating a satisfying safety of the sys-
temic and biological drugs used in Germany for moderate-
to-severe psoriasis.
Fig. 4 Rates of malignancies in psoriasis patients with systemic and biological drugs, including all malignancies except non-melanoma skin
cancer (top), non-melanoma skin cancer (middle), and melanoma skin cancer (bottom); n = 2444, bars show confidence interval
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